{
    "Project Title": "Not Available",
    "Sponsor": "Not Available",
    "Study Number": "2014-0546",
    "Protocol Version and Date": "Not Available",
    "Study Title": "Phase II Study of Oral Rigosertib in Patients with Myelofibrosis and Anemia",
    "Phase": "Phase II",
    "Therapeutic Area": "Myelofibrosis",
    "Number of Patients": "35",
    "Number of Sites": "5",
    "Indication": "Myelofibrosis with anemia",
    "Duration of Treatment": "Up to 48 weeks",
    "Schedule of Assessments": "Appendix 6",
    "questionnaires": [
        {
            "longName": "Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score",
            "shortName": "MPN-SAF TSS",
            "type": "PRO",
            "questionnaireSchedule": "Screening, Baseline/C1D1, QW, Q4W for 12 Weeks, then Q8W, Week 24 and Week 48"
        },
        {
            "longName": "ECOG Performance Status",
            "shortName": "ECOG",
            "type": "ClinRO",
            "questionnaireSchedule": "Screening, Baseline/C1D1, QW, Q4W for 12 Weeks, then Q8W, Week 24 and Week 48"
        }
    ]
}